TrianglePembrolizumab (NCT05155033)
Pembrolizumab trial for Metastatic Melanoma (NCT05155033). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people aged 18–120 with advanced, unresectable melanoma or metastatic clear-cell kidney cancer. Melanoma may be anti-PD-1-naive or refractory; kidney cancer must resist prior PD-1/PD-L1 treatment.
The idea: aldesleukin stimulates immunity while pembrolizumab releases immune inhibition. Initial intravenous combination treatment requires hospital stays. Patients without progression may then receive pembrolizumab alone, if appropriate.
This phase 2 study plans 78 patients. Stephanie Goff leads at the NIH Clinical Center in Bethesda, the sole recruiting US site. Researchers assess tumor response, progression and toxicity.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.